1. US HIV Drugs Market - Prevalence and Statistics

2. US HIV Drugs Market Overview

  2.1 Current Market Scenario

  2.2 Clinical Trials Landscape

3. US Nucleoside Reverse Transcriptase Inhibitors (NRTIs) - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  3.1 Abacavir (Ziagen)

  3.2 Emtricitabine (Emtriva)

  3.3 Lamivudine (Epivir)

  3.4 Tenofovir Disoproxil Fumarate (Viread)

  3.5 Zidovudine (Retrovir)

  3.6 Stavudine (Zerit)

  3.7 Didanosine (Videx/Videx EC)

4. US Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  4.1 Doravirine  (Pifeltro)

  4.2 Efavirenz  (Sustiva)

  4.3 Etravirine (Intelence)

  4.4 Rilpivirine  (Edurant)

  4.5 Nevirapine (Viramune/Viramune XR)

5. US Protease Inhibitors (PIs) - Branded and Generic Availability, Dosage, Patent, and Price Analysis

  5.1 Atazanavir (Reyataz)

  5.2 Darunavir  (Prezista)

  5.3 Fosamprenavir (Lexiva)

  5.4 Ritonavir (Norvir)

  5.5 Saquinavir (Invirase)

  5.6 Tipranavir  (Aptivus)

  5.7 Nelfinavir (Viracept)

  5.8 Amprenavir (Agenerase)

  5.9 Indinavir (Crixivan)

6. US Fusion Inhibitors - Branded and Generic Availability, Dosage, Patent, and Price Analysis

  6.1 Enfuvirtide (Fuzeon)

7. US CCR5 Antagonists - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  7.1 Maraviroc (Selzentry)

8. US Integrase Inhibitors - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  8.1 Dolutegravir  (Tivicay)

  8.2 Raltegravir (Isentress/Isentress HD)

9. US Attachment Inhibitors - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  9.1 Ibalizumab-Uiyk (Trogarzo)

  9.2 Fostemsavir (Rukobia)

10. US Pharmacokinetic Enhancers - Availability, Dosage, Patent and Price Analysis

  10.1 Cobicistat (Tybost)

11. US Combinational HIV Drugs - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  11.1 Abacavir/Lamivudine (Epzicom)

  11.2 Abacavir/Dolutegravir/Lamivudine (Triumeq)

  11.3 Abacavir/Lamivudine/Zidovudine) Trizivir

  11.4 Atazanavir/Cobicistat (Evotaz)

  11.5 Bictegravir/ Emtricitabine/ Tenofovir Alafenamide (Biktarvy)

  11.6 Cobicistat/Darunavir (Prezcobix)

  11.7 Cobicistat/Darunavir/Emtricitabine/Tenofovir (Symtuza)

  11.8 Dolutegravir/Lamivudine (Dovato)

  11.9 Dolutegravir/Rilpivirine (Juluca)

  11.10 Doravirine/Lamivudine/Tenofovir (Delstrigo)

  11.11 Efavirenz/Emtricitabine/Tenofovir (Atripla)

  11.12 Efavirenz/Lamivudine/Tenofovir Disoproxil Fumarate (Symfi/Simfi Lo)

  11.13 Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide Fumarate 

  (Genvoya)

  11.14 Cobicistat/ Elvitegravir/ Emtricitabine/ Tenofovir (Stribild)

  11.15 Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide (Odefsey)

  11.16 Emtricitabine/Rilpivirine/Tenofovir (Complera)

  11.17 Emtricitabine/Tenofovir Alafenamide (Descovy)

  11.18 Emtricitabine/Tenofovir (Truvada)

  11.19 Lamivudine/Tenofovir

  11.20 Lamivudine/Zidovudine (Combivir)

  11.21 Lopinavir/Ritonavir (Kaletra)

  11.22 Cabotegravir/Rilpivirine (Cabenuva)

  11.23 Emtricitabine / Nelfinavir / Tenofovir Oral  Kit

  11.24 Emtricitabine / Lopinavir / Ritonavir / Tenofovir Oral Kit

12. Compititive Landscape

  12.1 AbbVie

  12.2 AstraZeneca plc

  12.3 Boehringer Ingelheim

  12.4 Bristol Myers Squibb

  12.5 Gilead

  12.6 GlaxoSmithKline plc

  12.7 Janssen Pharmaceuticals

  12.8 Merck

  12.9 Pfizer

  12.10 Roche

  12.11 Sun Pharma

  12.12 ViiV Healthcare

Figure 1-1: US – Number of HIV Cases (Million), 2012, 2014 and 2018

Figure 1-2: US – Estimated Number of HIV Cases (Million), 2020, 2025 and 2030

Figure 1-3: US – Number of Newly Diagnosed HIV Cases and Deaths, 2018

Figure 1-4: US – Estimated Number of Newly Diagnosed HIV Cases, 2018, 2020 and 2025

Figure 1-5: US – Estimated Number of HIV Deaths, 2018, 2020 and 2025

Figure 1-6: US – HIV Incidence Rate (Per 100’000), 2014, 2018 and 2020

Figure 1-7: US – HIV Incidence Rate by Age Group (Per 100’000), 2018

Figure 1-8: US – HIV Incidence Rate by Race (Per 100’000), 2018

Figure 1-9: US – HIV Incidence Rate by Gender (Per 100’000), 2018

Figure 1-10: US – HIV Cases by Mode of Transmission (%), 2018

Figure 1-11: US – Percentage of HIV Patients by Nature of Treatment (%), 2018

Figure 2-1: Global – HIV Drug Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-2: Global – HIV Drug Market Size by Region (US$ Billion), 2020

Figure 2-3: Global – HIV Drug Market Size by Region (US$ Billion), 2020

Figure 2-4: North America – HIV Drug Market Size US v/s Others (US$ Billion), 2020

Figure 2-5: US – HIV Drug Market Opportunity (US$ Billion), 2020 - 2026

Figure 2-6: US - Number of  HIV Infection Drug Clinical Pipeline by Phase, 2021 - 2026

Figure 2-7: US - Number of HIV Infection Drugs in Clinical Pipeline by Drug Class, 2021 - 2026

Figure 2-8: US - Number of HIV Infection Drugs in Clinical Pipeline by Organization, 2021 - 2026

Figure 2-9: US - Number of HIV Infection Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026

Figure 3-1: Ziagen – FDA Approval and First Generic Approval Year

Figure 3-2: Ziagen Oral Solution – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 3-3:  Ziagen Tablet – Price for 60 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-4: Generic Abacavir Oral Solution – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 3-5:  Generic Abacavir Tablet – Price for 60 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-6: Ziagen – Daily Treatment Cost by Dosage Form (US$)

Figure 3-7:  Ziagen – Pediatric Dosage form by Weight (mg/day)

Figure 3-8: Emtriva – FDA Approval Year by Dosage Form

Figure 3-9: US - Emtriva Patent Issue and Expiration Year

Figure 3-10: Emtriva Oral Solution – Price for 170ml Supply and Price Per ml (US$), February’2021

Figure 3-11:  Emtriva Tablet – Price for 30 Capsules and Price Per Unit Capsule (US$), February’2021

Figure 3-12: Emtriva – Daily Dose by Dosage Form (mg)

Figure 3-13: Emtriva: Daily Treatment Cost by Dosage Form (US$), February’2021

Figure 3-14: Epivir: FDA Approval Year by Dosage Form

Figure 3-15: Epivir: First Generic Approval Year by Dosage Form

Figure 3-16: Epivir Oral Solution – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 3-17:  Epivir 150mg Tablet – Price for 60 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-18: Epivir 300mg Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-19: Generic Lamivudine Oral Solution – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 3-20:  Generic Lamivudine 150mg Tablet – Price for 60 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-21:  Generic Lamivudine 150mg Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-22:  Generic Lamivudine 150mg Tablet – Price for 50 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-23: Generic Lamivudine 300mg Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 3-24: Epivir: Daily Treatment Cost by Dosage Form (US$), February’2021

Figure 3-25:  Epivir – Pediatric Dosage form by Weight (mg/day)

Figure 3-26: Viread - FDA Approval Year by Dosage Form

Figure 3-27: Viread – First Generic Approval Year by Dosage Form

Figure 3-28: Viread Oral Powder – Price for 60 gm Supply and Price Per gm (US$), Februray’2021

Figure 3-29:  Viread 300 mg Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), Februray’2021

Figure 3-30: Viread Tablet – Price for 30 Tablets of 150,200 and 250mg Dose and Price Per Unit Tablet (US$), Februray’2021

Figure 3-31:  Generic Viread 300 mg Tablet – Average Price for 28 Tablets and Price Per Unit Tablet (US$), Februray’2021

Figure 3-32:  Generic Viread 300 mg Tablet – Average Price for 30 Tablets and Price per Unit Tablet (US$), Februray’2021

Figure 3-33:  Generic Viread 300 mg Tablet – Average Price for 60 Tablets and Price Per Unit Tablet (US$), Februray’2021

Figure 3-34:  Generic Viread 300 mg Tablet – Average Price for 90 Tablets and Price Per Unit Tablet (US$), Februray’2021

Figure 3-35:  Generic Viread 300 mg Tablet – Average Price for 180 Tablets and Price Per Unit Tablet (US$), Februray’2021

Figure 3-36: Viread Tablet – Pediatric Dose by Weight (mg/day)

Figure 3-37: Viread Oral Powder – Pediatric Dosage form by Weight (mg/day)

Figure 3-38: Viread - Daily Treatment Cost by Dosage Form (US$), February’2021

Figure 3-39: Global - Viread Annual Sales Value (US$ Million), 2017 - 2020

Figure 3-40: US - Viread Annual Sales Value (US$ Million), 2017 - 2020

Figure 3-41: Global - Viread Annual Sales Value by Region (US$ Million), 2020

Figure 3-42: Global - Viread Annual Sales Value by Region (%), 2020

Figure 3-43: Global - Viread Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 3-44: US - Viread Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 3-45: Retrovir - FDA Approval Year by Dosage Form

Figure 3-46: Retrovir – First Generic Approval Year by Dosage Form

Figure 3-47: Retrovir Intravenous Solution – Price for 100 ml Supply and Price Per ml (US$), February’2021

Figure 3-48:  Retrovir Capsule – Price for 100 Capsules and Price Per Unit Capsule (US$), February’2021

Figure 3-49: Retrovir Syrup – Price for 240ml and Price Per ml (US$), February’2021

Figure 3-50: Generic Zidovudine Tablet – Price for 60 Tablets Supply and Price Per Unit Tablet (US$), February’2021

Figure 3-51:  Generic Zidovudine Capsule – Price for 100 Capsules and Price Per Unit Capsule (US$), February’2021

Figure 3-52: Generic Zidovudine Syrup – Price for 240ml and Price Per ml (US$), February’2021

Figure 3-53: Retrovir Capsule – Daily, Monthly and Annual Treatment Cost (US$), February’2021

Figure 3-54: Retrovir – Oral Pediatric Dosage form by Weight (mg/Kg/day)

Figure 3-55: Zerit – FDA and First Generic Approval Year

Figure 3-56: Zerit – FDA Approval Year by Dosage Forms

Figure 3-57: Zerit – Price for 60 Capsule Supply and Price Per Unit Capsule of 15mg Dose (US$), February’2021

Figure 3-58: Zerit – Price for 60 Capsule Supply and Price Per Unit Capsule of 20mg Dose (US$), February’2021

Figure 3-59: Zerit – Price for 60 Capsule Supply and Price Per Unit Capsule of 30mg Dose (US$), February’2021

Figure 3-60:  Zerit – Price for 60 Capsules and Price Per Unit Capsule (US$), February’2021

Figure 3-61: Generic Stavudine – Price for 60 Capsules of Various Dose Regimens (US$), February’2021

Figure 3-62: Zerit – Daily Adult Dose by Weight (mg)

Figure 3-63: Zerit – Minimum and Maximum Daily Treatment Cost (US$), February’2021

Figure 3-64: Zerit – Pediatric Dose by Age (mg/kg Twice Daily)

Figure 3-65: Videx - FDA Approval Year by Dosage Form

Figure 3-66: Videx Oral Powder for Reconstitution – Price for 200ml Supply and Price Per ml (US$), February’2021

Figure 3-67: Videx EC – Price for 30 Capsule Supply and Price Per Unit Capsule (US$), February’2021

Figure 3-68: Generic Videx EC – Price for 30 Capsule Supply and Price Per Unit Capsule (US$), February’2021

Figure 3-69: Videx – Daily Adult Dose by Weight (mg)

Figure 3-70: Videx – Minimum and Maximum Daily Treatment Cost (US$), February’2021

Figure 3-71: Videx – Pediatric Dose by Age (mg/m2 Daily)

Figure 3-72: Videx – Adult Dose by Weight (mg)

Figure 4-1: Pifeltro – FDA Approval Year by Type of Therapy

Figure 4-2: US - Pifeltro Patent Issue and Expiration Year

Figure 4-3: Pifeltro – Price for 30 Capsules and Price Per Unit Capsule (US$), February’2021

Figure 4-4: Pifeltro – Recommended Dose by Type of Therapy (mg/day)

Figure 4-5: Sustiva – FDA Approval Year by Dosage Form

Figure 4-6: Sustiva – First Generic Approval Year by Dosage Form

Figure 4-7: Sustiva Capsules – Price for 30 Capsule Supply and Price Per Unit Capsule of 50mg Dose (US$), February’2021

Figure 4-8: Sustiva Capsules – Price for 90 Capsule Supply and Price Per Unit Capsule of 200mg Dose (US$), February’2021

Figure 4-9:  Sustiva Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 4-10: Generic Efavirenz Capsules – Price for 30 Capsule Supply and Price Per Unit Capsule of 50mg Dose (US$), February’2021

Figure 4-11: Generic Efavirenz Capsules – Price for 90 Capsule Supply and Price Per Unit Capsule of 200mg Dose (US$), February’2021

Figure 4-12:  Generic Efavirenz Tablet – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 4-13: Sustiva – Recommended Adult Dose by Type of Therapy (mg/day), February’2021

Figure 4-14: Sustiva – Recommended Pediatric Dose by Weight (mg/day), February’2021

Figure 4-15: Intelence – FDA Approval Year by Dosage Form

Figure 4-16: US - Intelence Patent Issue and Expiration Year

Figure 4-17: Intelence – Price for 120 Tablets and Price Per Unit of 25mg and 100mg Tablet (US$), February’2021

Figure 4-18: Intelence – Price for 60 Tablets and Price Per Unit of 200mg Tablet (US$), February’2021

Figure 4-19: Intelence – Daily, Monthly and Annual treatment Cost (US$), February’2021

Figure 4-20: Intelence – Recommended Pediatric Dose by Weight (mg/day), February’2021

Figure 4-21: Edurant – Jassen’s US Patent Issue and Expiration Year

Figure 4-22: Edurant – AstraZeneca’s US Patent Issue and Expiration Year

Figure 4-23: Edurant – Price for 30 Tablet Supply and Price Per Unit Tablet of 25mg (US$), February’2021

Figure 4-24: Edurant – Daily Dose by Type of Therapy (mg), February’2021

Figure 4-25: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020

Figure 4-26: Global - Edurant Annual Sales Value (US$ Million), 2016 - 2020

Figure 4-27: Global - Edurant Annual Sales Value by Region (US$ Million), 2020

Figure 4-28: Global - Edurant Annual Sales Value by Region (%), 2020

Figure 4-29: Global - Edurant Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 4-30: US - Edurant Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 4-31: Viramune – FDA Approval Year by Dosage Form

Figure 4-32: Viramune – First Generic Approval by Dosage Form

Figure 4-33: Viramune Suspension – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 4-34: Viramune Tablet 200mg – Price for 60 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 4-35:  Viramune XR Tablet 400mg – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 4-36: Generic Nevirapine Suspension – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 4-37: Generic Nevirapine Tablet 200mg – Price for 60 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 4-38:  Generic Tablet 400mg – Price for 30 Tablets and Price Per Unit Tablet (US$), February’2021

Figure 4-39: Viramune – Oral Dose by Treatment Phase (mg/day), February’2021

Figure 4-40: Viramune – Recommended Pediatric Dose by Surface Area (mg/day), February’2021

Figure 5-1: Reyataz – FDA approval Year by Dosage Form

Figure 5-2: Reyataz Capsules – Price for 60 Capsule and Price Per Unit Capsule of 150 to 200mg (US$), February’2021

Figure 5-3: Reyataz Capsules – Price for 30 Capsule and Price Per Unit Capsule of 300mg (US$), February’2021

Figure 5-4: Reyataz Powder – Price for 30 Supply and Price Per Unit Oral Powder (US$), February’2021

Figure 5-5: Atazanavir Capsules – Price for 60 Capsule and Price Per Unit Capsule of 150 to 200mg (US$), February’2021

Figure 5-6: Atazanavir Capsules – Price for 30 Capsule and Price Per Unit Capsule of 300mg (US$), February’2021

Figure 5-7: Reyataz – Dose by Treatment Therapy (mg/day), February’2021

Figure 5-8: Reyataz – Recommended Pediatric Dose by Weight (mg/day), February’2021

Figure 5-9: Prezista – FDA approval Year by Dosage Form

Figure 5-10: US - Prezista Patent Issue and Expiration Year by Assignee

Figure 5-11: Prezista Suspension – Price for a Supply of 200ml and Price Per ml (US$), February’2021

Figure 5-12: Prezista Tablet – Price per unit of Various Doses (US$), February’2021

Figure 5-13: Reyataz – Dose by Type of HIV Patient (mg/day), February’2021

Figure 5-14: Reyataz – Daily Treatment Cost for Treatment Naandiuml;ve Patients by Dosage Form (mg/day), February’2021

Figure 5-15: Lexiva – FDA approval Year by Dosage Form

Figure 5-16: Lexivia Suspension – Price for a Supply of 225ml and Price Per ml (US$), February’2021

Figure 5-17: Lexivia Tablet – Price for 60 Tablet Supply and Price Per Unit (US$), February’2021

Figure 5-18: Generic Fosamprenavir Tablet – Price for 60 Tablet Supply and Price Per Unit (US$), February’2021

Figure 5-19: Lexivia – Dose by Treatment Therapy (mg/day), February’2021

Figure 5-20: Lexivia – Recommended Pediatric Dose by Weight (mg/Kg Twice daily), February’2021

Figure 5-21: Norvir – FDA approval Year by Dosage Form

Figure 5-22: US - Norvir Patent Issue and Expiration Year

Figure 5-23: Norvir Powder – Price for a Supply of 30 Powders and Price Per Unit (US$), February’2021

Figure 5-24: Norvir Tablet – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 5-25: Norvir Solution – Price for 240ml Supply and Price Per ml (US$), February’2021

Figure 5-26: Generic Ritonavir Tablet – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 5-27: Norvir – Daily Treatment Cost by Dosage Form (US$), February’2021

Figure 5-28: Norvir – FDA approval Year by Dosage Form

Figure 5-29: Invirase Tablet – Price for 120 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 5-30: Invirase Tablet – Daily Dose During Initial 7 days v/s After 7 Days (mg/day), February’2021

Figure 5-31: Invirase Tablet – Daily Treatment Cost During Initial Week v/s After Initial Week (mg/day), February’2021

Figure 5-32: Aptivus – FDA approval Year by Dosage Form

Figure 5-33: Aptivus – Price for 120 Capsule Supply and Price Per Unit Capsule (US$), February’2021

Figure 5-34: Aptivus Solution – Price for 95ml Supply and Price Per ml (US$), February’2021

Figure 5-35: Aptivus – Daily Treatment Cost by Dosage Form (US$), February’2021

Figure 5-36: Viracept - FDA approval Year by Dosage Form

Figure 5-37: Viracept – Price for a Supply of 300 Tablets and Price Per Unit Tablet of 250mg (US$), February’2021

Figure 5-38: Viracept – Price for a Supply of 120 Tablets and Price Per Unit Tablet of 625mg (US$), February’2021

Figure 5-39: Viracept – Daily Minimum and Maximum Dose (mg), February’2021

Figure 5-40: Viracept Tablet – Daily Minimum and Maximum Treatment Cost (US$), February’2021

Figure 5-41: Agenerase – FDA Approval and Patent Expiration Year

Figure 5-42: Agenerase – Price for 480 Capsule Supply and Price Per Unit Capsule of 50 mg (US$), February’2021

Figure 5-43: Agenerase – Recommended Dose by Type of Therapy (mg), February’2021

Figure 5-44: Crixivan - FDA approval Year by Dosage Form

Figure 5-45: Crixivan – Patent Issue and Expiration Year

Figure 5-46: Crixivan – Price for a Supply of 360 Capsules and Price Per Unit Capsules of 200mg (US$), February’2021

Figure 5-47: Crixivan – Price for a Supply of 180 Capsules and Price Per Unit Capsules of 400mg (US$), February’2021

Figure 5-48: Crixivan – Recommended Dose by Therapy Type (mg/day), February’2021

Figure 5-49: Crixivan – Average cost of Single Dose and Daily Treatment Cost (US$), February’2021

Figure 6-1: US - Fuzeon Patent Issue and Expiration Year

Figure 6-2: Fuzeon – Price for a Supply of 60 Powders and Price Per Unit of 90mg Powder (US$), February’2021

Figure 6-3: Fuzeon – Cost of Daily, Monthly and Annual Treatment (US$), February’2021

Figure 7-1: Selzentry - FDA approval Year by Dosage Form

Figure 7-2: US - Selzentry Patent Issue and Expiration Year

Figure 7-3: Selzentry Oral Liquid - Price for a Supply of 230 ml and Price Per ml of 90mg (US$), February’2021

Figure 7-4: Selzentry Tablets - Price for a Supply of 120 Tablets and Price Per Unit of 25mg and 75mg Tablet (US$), February’2021

Figure 7-5: Selzentry Tablets - Price for a Supply of 120 Tablets and Price Per Unit of 150mg and 300mg Tablet (US$), February’2021

Figure 7-6: Selzentry – Daily Dose by Combination Agent (mg), February’2021

Figure 7-7: Selzentry – Daily Pediatric Dose in Combination in Combination with Potent CYP450 3A Inhibitors by Weight (mg), February’2021

Figure 7-8: Global - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 7-9: US - Selzentry Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 7-10: Selzentry – Annual Sales Value by Region (US$/GBP Million), 2020

Figure 7-11: Selzentry – Annual Sales Value by Region (%), 2020

Figure 7-12: Global - Selzentry Quarterly Sales Value (US$/GBP Million), 2020

Figure 7-13: US - Selzentry Quarterly Sales Value (US$/GBP Million), 2020

Figure 8-1: Tivicay - FDA approval Year by Dosage Form

Figure 8-2: US - Tivicay Patent Issue and Expiration Year

Figure 8-3: Tivicay - Price for a Supply of 30 Tablets and Price Per Unit Tablet of Various Doses (US$), February’2021

Figure 8-4: Tivicay – Minimum and Maximum Daily Dose (mg), February’2021

Figure 8-5: Tivicay – Minimum and Maximum Daily Treatment Cost (US$), February’2021

Figure 8-6: Tivicay – Pediatric Dose by Weight of Patient (mg), February’2021

Figure 8-7: Global - Tivicay Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 8-8: Global - Tivicay Annual Sales Value by Region (US$/GBP Million), 2020

Figure 8-9: Global - Tivicay Annual Sales Value by Region (%), 2020

Figure 8-10: Global - Tivicay Quarterly Sales Value (US$/GBP Million), 2020

Figure 8-11: US - Tivicay Quarterly Sales Value (US$/GBP Million), 2020

Figure 8-12: Isentress - FDA approval Year by Dosage Form

Figure 8-13: Isentress – Istituto Di Ricerche Di Biologia Molecolare’s Patent Issue and Expiration Year

Figure 8-14: Isentress – Merck’s Patent Issue and Expiration Year

Figure 8-15: Isentress – Price for 60 Granule Supply and Price Per Unit of 100mg Granules (US$), February’2021

Figure 8-16: Isentress – Price for 60 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 8-17: Isentress - Price for a Supply of 60 Chewable Tablets and Price Per Unit Tablet of Various Doses (US$), February’2021

Figure 8-18: Isentress HD – Price for 60 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 8-19: Isentress – Recommended Dose by Patient Type (mg/day), February’2021

Figure 8-20: Global - Isentress/Isentress HD Annual Sales Value (US$ Million), 2017 - 2020

Figure 8-21: Global - Isentress Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 9-1: Trogarzo – FDA Approval and Patent Expiration Year

Figure 9-2: Trogarzo – Price for 2.66ml Supply and Price Per ml of Intravenous Solution (US$), February’2021

Figure 9-3: Trogarzo – Loading Dose v/s Maintenance Dose (mg/2 Weeks), February’2021

Figure 9-4: Trogarzo – Cost of Loading Dose v/s Maintenance Dose (US$), February’2021

Figure 9-5: Global - Trogarzo Annual Sales (US$ Million), 2018 and 2019

Figure 9-6: US - Rukobia Patent Issue and Expiration Year

Figure 9-7: Rukobia – Price for 60 Tablets Supply and Price Per Unit of 600mg Tablet (US$), Februray’2021

Figure 9-8: Rukobia – Cost of Daily and Monthly Treatment (US$), Februray’2021

Figure 10-1: US - Tybost Patent Issue and Expiration Year

Figure 10-2: Tybost – Price for 30 Tablets Supply and Price Per Unit of 150mg (US$), February’2021

Figure 11-1: Epzicom – FDA Approval and First Generic Approval

Figure 11-2: Epzicom – Price for 30 Tablets Supply and Price per unit Tablet (US$), February’2021

Figure 11-3: Generic Abacavir/Lamivudine – Price for 30 Tablets Supply and Price Per Unit of 150mg (US$), February’2021

Figure 11-4: Epzicom – Daily, Monthly and Annual Treatment Cost (US$), February’2021

Figure 11-5: Global - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 – 2020

Figure 11-6: US - Epzicom/Kivexa Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 11-7: Epzicom/Kivexa – Annual Sales Value by Region (US$/GBP Million), 2020

Figure 11-8: Epzicom/Kivexa – Annual Sales Value by Region (%), 2020

Figure 11-9: Global - Epzicom/Kivexa Quarterly Sales Value (US$ Million), 2020

Figure 11-10: US – Triumeq Patent Issue and Expiration Year

Figure 11-11: Epzicom – Price for 30 Tablets Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-12: Global - Triumeq Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-13: US - Triumeq Annual Sales Value by Region (US$/GBP Million), 2020

Figure 11-14: Triumeq – Annual Sales Value by Region (%), 2020

Figure 11-15: Global - Triumeq Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-16: US - Triumeq Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-17: Trizivir – FDA Approval and First Generic Approval

Figure 11-18: Trizivir – Price for 60 Tablets Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-19: Generic Trizivir – Price for 60 Tablets Supply and Price Per Unit of 150mg (US$), February’2021

Figure 11-20: Trizivir – Daily, Monthly and Annual Treatment Cost (US$), February’2021

Figure 11-21: US - Evotaz Patent Issue and Expiration Year

Figure 11-22: Evotaz – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-23: Biktarvy – Gilead’s US Patent Issue and Expiration Year

Figure 11-24: Biktarvy – Emory’s US Patent Issue and Expiration Year

Figure 11-25: Biktarvy – Price for 30 tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-26: Global - Biktarvy Annual Sales Value (US$ Billion), 2018 - 2020

Figure 11-27: Global - Biktarvy Annual Sales Value by Region (US$ Million), 2020

Figure 11-28: Biktarvy – Annual Sales Value by Region (%), 2020

Figure 11-29: Global - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020

Figure 11-30: US - Biktarvy Quarterly Sales Value (US$ Million), 2019 - 2020

Figure 11-31: Prezcobix – Gilead’s US Patent Issue and Expiration Year

Figure 11-32: Prezcobix – Tibotic’s US Patent Issue and Expiration Year

Figure 11-33: Prezcobix – Janssen’s US Patent Issue and Expiration Year

Figure 11-34: Prezcobix – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-35: Symtuza – Gilead’s US Patent Issue and Expiration Year

Figure 11-36: Symtuza – Emory’s US Patent Issue and Expiration Year

Figure 11-37: Symtuza - Tibotic’s US Patent Issue and Expiration Year

Figure 11-38: Symtuza – Janssen’s US Patent Issue and Expiration Year

Figure 11-39: Symtuza – Price for 30 tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-40: Dovato – GSK’s US Patent Issue and Expiration Year

Figure 11-41: Dovato – VIIV’s US Patent Issue and Expiration Year

Figure 11-42: Dovato – Price for 30 tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-43: Global - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 and2020

Figure 11-44: US - Dovato Annual Sales Value by Region (US$/GBP Million), 2019 and 2020

Figure 11-45: Dovato – Annual Sales Value by Region (US$/GBP Million), 2020

Figure 11-46: Dovato – Annual Sales Value by Region (%), 2020

Figure 11-47: Global - Dovato Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-48: US - Dovato Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-49: US - Juluca Number of Patent Issued by Assignee Name

Figure 11-50: US - Juluca Patent Expiration Year by Assignee

Figure 11-51: Juluca – Price for 30 tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-52: Global - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 11-53: US - Juluca Annual Sales Value (US$/GBP Million), 2017 - 2020

Figure 11-54: Juluca – Annual Sales Value by Region (US$/GBP Million), 2020

Figure 11-55: Juluca – Annual Sales Value by Region (%), 2020

Figure 11-56: Global - Juluca Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-57: US - Juluca Quarterly Sales Value (US$/GBP Million), 2020

Figure 11-58: US - Delstrigo Patent Issue and Expiration Year

Figure 11-59: Delstrigo – Price for 30 tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-60: Delstrigo – Daily, Monthly and Annual Treatment Cost (US$), February’2021

Figure 11-61: Atripla – FDA approval and Generic Approval Year

Figure 11-62: Alripla - Gilead’s US Patent Issue and Expiration Year

Figure 11-63: Atripla – Emory’s US Patent Issue and Expiration Year

Figure 11-64: Atripla – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-65: Generic Atripla – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-66: Global - Atripla Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-67: US - Atripla Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-68: Atripla – Annual Sales Value by Region (US$ Million), 2020

Figure 11-69: Atripla – Annual Sales Value by Region (%), 2020

Figure 11-70: Global - Atripla Quarterly Sales Value (US$ Million), 2020

Figure 11-71: US - Atripla Quarterly Sales Value (US$ Million), 2020

Figure 11-72: Simfi/Simfi Lo – FDA approval Year

Figure 11-73: Simfi/Simfi Lo – Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-74: Genvoya – Number of US Patent Issued by Assignee Name

Figure 11-75: Genvoya – US Patent Expiration Year by Assignee

Figure 11-76: Genvoya - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-77: Global - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020

Figure 11-78: US - Genvoya Annual Sales Value (US$ Billion), 2017 - 2020

Figure 11-79: Genvoya – Annual Sales Value by Region (US$ Million), 2020

Figure 11-80: Genvoya – Annual Sales Value by Region (%), 2020

Figure 11-81: Global - Genvoya Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-82: US - Genvoya Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-83: Stribild - Number of US Patent Issued by Assignee Name

Figure 11-84: US – Stribild Patent Expiration Year by Assignee

Figure 11-85: Stribild - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-86: Global - Stribild Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-87: US - Stribild Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-88: Stribild - Annual Sales Value by Region (US$ Million), 2020

Figure 11-89: Stribild – Annual Sales Value by Region (%), 2020

Figure 11-90: Global - Stribild Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-91: US - Stribild Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-92: Odefsey - Number of US Patent Issued by Assignee Name

Figure 11-93: US - Odefsey Patent Expiration Year by Assignee

Figure 11-94: Odefsey - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-95: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-96: Global - Odefsey Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-97: Odefsey - Annual Sales Value by Region (US$ Million), 2020

Figure 11-98: Odefsey – Annual Sales Value by Region (%), 2020

Figure 11-99: Global - Odefsey Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-100: US - Odefsey Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-101: Complera - Number of US Patent Issued by Assignee Name

Figure 11-102: Complera – US Patent Expiration Year by Assignee

Figure 11-103: Complera - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-104: Complera – Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-105: Complera - Annual Sales Value by Region (US$ Million), 2020

Figure 11-106: Complera – Annual Sales Value by Region (%), 2020

Figure 11-107: Global - Complera Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-108: US - Complera Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-109: Descovy - Number of US Patents Issued by Assignee Name

Figure 11-110: Descovy – US Patent Expiration Year by Assignee

Figure 11-111: Descovy - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-112: Descovy - Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-113: Descovy - Annual Sales Value by Region (US$ Million), 2020

Figure 11-114: Descovy – Annual Sales Value by Region (%), 2020

Figure 11-115: Global - Descovy Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-116: US - Descovy Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-117: Truvada - Number of US Patent Issued by Assignee Name

Figure 11-118: US - Descovy Patent Expiration Year by Assignee

Figure 11-119: Truvada: Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-120: Truvada - Annual Sales Value (US$ Million), 2017 - 2020

Figure 11-121: Truvada - Annual Sales Value by Region (US$ Million), 2020

Figure 11-122: Truvada – Annual Sales Value by Region (%), 2020

Figure 11-123: Global - Truvada Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-124: US - Truvada Quarterly Sales Value (US$ Million), 2019 and 2020

Figure 11-125: Cimduo - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-126: Temixys - Price for 30 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-127: Combivir – FDA and First Generic Approval Year

Figure 11-128: Combivir - Price for 60 Tablet Supply and Price Per Unit Tablet (US$), February’2021

Figure 11-129: Generic Combivir - Price for various Supplies of Oral Tablet (US$), February’2021

Figure 11-130: Kaletra – FDA Approval Year by Dosage Form

Figure 11-131: Kaletra Oral Solution – Branded v/s Generic Price for 160 ml Supply and Price Per ml of (US$), February’2021

Figure 11-132: Kaletra Oral Tablet - Price for 60 Tablet and Price per unit Tablets of 100mg-25mg Dose (US$), February’2021

Figure 11-133: Kaletra Oral Tablet - Price for 12 Tablet and 120 Tablet Supply of 200mg-50mg Dose (US$), February’2021

Figure 11-134: Cabenuva – Price for Various Supplies of Cabenuva Suspension Kit (US$), February’2021

Figure 11-135: Cabenuva – Recommended Initial and Subsequent Dose (mg/Month),

Figure 11-136:  Emtricitabine / Nelfinavir / Tenofovir Oral Kit – Price Per Unit by Product (US$), February’2021

Figure 11-137:  Emtricitabine / Nelfinavir / Tenofovir Oral Kit – Price Per Unit by Product (US$), February’2021